Edgar Flores, MD
Pediatric Medicine · Fullerton, CANPI 1992857239
Payments from drug & device makers
Across 641 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- Novo Nordisk$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- GSK$660
- plus $5K from 32 others
What the payments were for
- Travel & lodging$20%
- Food & beverage$12,704100%
- Education$140%
- Gifts$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 124 | $1,837 |
| Johnson & Johnson(2 entities) | 105 | $1,419 |
| Novo Nordisk | 90 | $1,409 |
| AstraZeneca | 25 | $1,037 |
| Lilly USA, LLC | 46 | $1,005 |
| GSK | 26 | $660 |
| Boehringer Ingelheim | 32 | $628 |
| Merck | 28 | $577 |
| AbbVie(2 entities) | 22 | $560 |
| Bayer | 13 | $487 |
| Pfizer | 24 | $475 |
| Boston Scientific | 13 | $423 |
| Dexcom, Inc. | 12 | $373 |
| Abbott | 7 | $355 |
| Eisai Inc. | 11 | $264 |
| Exact Sciences | 10 | $210 |
| Sanofi-aventis U.S. LLC | 9 | $172 |
| Xeris Pharmaceuticals, Inc. | 7 | $145 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $95 |
| Sanofi Pasteur Inc. | 6 | $89 |
| Medtronic | 2 | $58 |
| Shield Therapeutics Inc | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Novartis | 2 | $45 |
| Linus Health, Inc. | 1 | $44 |
| Corcept Therapeutics | 2 | $38 |
| Optos, Inc. | 2 | $35 |
| Abiomed | 1 | $29 |
| Cranial Technologies, Inc | 2 | $26 |
| Roche Diagnostics Corporation | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Biogen | 1 | $18 |
| Smith+Nephew | 1 | $16 |
| Oxford Immunotec USA Inc | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
| Metacel Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,733 in reported general payments places this provider in the 95th percentile of 52 pediatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 203 | $322,919 |
| OzempicSemaglutide | 288 | $287,171 |
| MounjaroTirzepatide | 158 | $193,874 |
| XareltoRivaroxaban | 90 | $121,939 |
| FarxigaDapagliflozin Propanediol | 94 | $100,530 |
| OtezlaApremilast | 15 | $70,206 |
| TrulicityDulaglutide | 58 | $63,914 |
| RybelsusSemaglutide | 26 | $58,372 |
| EliquisApixaban | 31 | $44,428 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $44,390 |
| KerendiaFinerenone | 24 | $40,173 |
| Xigduo XrDapaglifloz Propaned/Metformin | 29 | $39,889 |
| JanuviaSitagliptin Phosphate | 24 | $36,850 |
| ProliaDenosumab | 15 | $25,594 |
| TradjentaLinagliptin | 19 | $25,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $628 | $347,962222 claims |
| Novo NordiskOzempic, Rybelsus | $1,409 | $345,543314 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,005 | $257,789216 claims |
| Johnson & JohnsonXarelto | $1,419 | $121,93990 claims |
| AstraZenecaFarxiga, Airsupra, Brilinta | $1,037 | $111,715120 claims |
| AmgenOtezla, Prolia | $1,837 | $95,80030 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $660 | $58,49795 claims |
| PfizerEliquis | $475 | $44,42831 claims |
| BayerKerendia | $487 | $40,17324 claims |
| MerckJanuvia | $577 | $36,85024 claims |
| AbbVieLinzess, Synthroid | $560 | $23,29970 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $46 | $7,24312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 pediatric medicine providers in California.
Other pediatric medicine in Fullerton
- Ulrike ZiegnerRedondo Beach$228K
- Rasiq AhmedPasadena$969
- Trach DangSan Jose$451
- Nirmita DoshiOakland$0
- Joyce ArpilledaSan Diego$0
- Anna EkstromFremont$0
- Patricia TanseyElk Grove$0
- Margaret KhouryBaldwin Park$0
- Charles PohlWest Hollywood$0
- Allan MarksSan Francisco$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.